AstraZeneca CEO Pascal Soriot Receives Vesting of Performance Share Award

AstraZeneca ( (GB:AZN) ) just unveiled an announcement.

AstraZeneca has disclosed that Chief Executive Officer Pascal Soriot received a vesting of 18,359 ordinary shares under the AstraZeneca Performance Share Plan, following a three-year performance period and a subsequent two-year holding period. The award, granted in May 2021 and linked to scientific, commercial, financial and sustainability metrics, vested at 88% after dividend reinvestment and tax-related share withholding, highlighting both the company’s long-term incentive alignment with performance and the adherence to market abuse regulations on executive share transactions.

The vesting, for nil consideration and based on a fair market value of 13,766 pence per share at the time of vest, reflects AstraZeneca’s continued emphasis on tying executive remuneration to multi-year outcomes, including sustainability performance. For investors and other stakeholders, the disclosure provides transparency into senior management incentives and reinforces regulatory compliance, while signalling that performance targets over the period were largely met, with a portion of the award lapsing due to unmet criteria.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on AZN Stock

According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.

The score is driven primarily by strong underlying fundamentals (profitability, margins, and returns) and a constructive earnings update with reiterated guidance and meaningful pipeline progress. These positives are partly offset by weak technical momentum, moderate valuation, and near-term cash/debt pressures tied to higher investment and payments.

To see Spark’s full report on AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK, focused on discovering, developing and commercialising prescription medicines across Oncology, Rare Disease and broader BioPharmaceuticals, including cardiovascular, renal, metabolic, respiratory and immunology therapies. Its products are sold in more than 125 countries and used by millions of patients worldwide, underscoring its significant presence in global healthcare markets.

Average Trading Volume: 2,604,419

Technical Sentiment Signal: Buy

Current Market Cap: £211.4B

See more insights into AZN stock on TipRanks’ Stock Analysis page.